ClinicalTrials.gg
CompletedNCT04303780Updated Jul 22, 2026Results posted

Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).

A Phase 3 interventional study of AMG 510 and Docetaxel in KRAS p, G12c Mutated /Advanced Metastatic NSCLC, sponsored by Amgen. Completed at 274 sites in 23 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-07-22.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
345
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Study summary

A Phase 3 Study to Compare AMG 510 with Docetaxel in Non Small Cell Lung Cancer (NSCLC) subjects with KRAS p. G12c mutation

02

Conditions studied

  • KRAS p, G12c Mutated /Advanced Metastatic NSCLC
03

In context

Lead sponsor

Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.

Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men or women greater than or equal to 18 years old.
  • ≤ 1
  • documented, previously treated, locally-advanced and unresectable or NSCLC with KRAS p.G12C mutation confirmed through central testing or have documentation of KRAS p.G12C mutation through Amgen Study 20190294 prior to enrollment

Exclusion criteria

Exclusion Criteria:

  • Active
  • Myocardial infarction within 6 months of study day 1
  • Gastrointestinal (GI) tract disease causing the inability to take oral medication
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
345 participants (actual)

Study arms

  • Experimental
    AMG 510

    Drug: AMG 510

  • Active comparator
    Docetaxel

    Drug: Docetaxel

Interventions

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS)

    PFS was defined as the time from randomization (baseline) until disease progression or death from any cause, whichever occurred first for all participants. Progression was based on blinded independent central review (BICR) of disease response per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1). As pre-specified in the statistical analysis plan, for participants who crossed over from docetaxel to AMG 510, the participant's response post first progression or post crossover was not used for the primary analyses. Data are presented per original treatment randomized.

    Time frame: Baseline up to primary analysis data cut-off date (02 August 2022); max time on study as of primary analysis data cut off was 24.3 months

07

Results

Posted May 10, 2023

Participant flow

345 participants were enrolled at 148 centers in Europe, North America, Asia, Australia, and South America. The analyses presented in this results summary are based on the primary completion data. The primary completion data cut-off was 02 August 2022. The study is ongoing.

Participant flow — Overall Study
MilestoneAMG 510Docetaxel
Started171174
Switched from docetaxel to amg 510046
Completed03
Not completed171171
Withdrew: Death10485
Withdrew: Lost to follow-up52
Withdrew: Withdrawal by subject1239
Withdrew: Ongoing in study5045

Outcome measures

PrimaryProgression-free Survival (PFS)

PFS was defined as the time from randomization (baseline) until disease progression or death from any cause, whichever occurred first for all participants. Progression was based on blinded independent central review (BICR) of disease response per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1). As pre-specified in the statistical analysis plan, for participants who crossed over from docetaxel to AMG 510, the participant's response post first progression or post crossover was not used for the primary analyses. Data are presented per original treatment randomized.

Time frame:
Baseline up to primary analysis data cut-off date (02 August 2022); max time on study as of primary analysis data cut off was 24.3 months
Reported as:
Median · months
Progression-free Survival (PFS)
monthsAMG 510Docetaxel
Progression-free Survival (PFS)5.62 (4.27 to 7.75)4.47 (3.02 to 5.68)
Statistical analysis
  • AMG 510 vs Docetaxel · Log Rank · p = 0.002 · Hazard ratio (hr): 0.663 · 95% CI 0.509 to 0.864

Adverse events

Collected over Adverse events:for 'Docetaxel' and 'AMG 510', from first dose(FD) to 30 days post last dose, or before FD of AMG 510 if participants cross over, or end of study (EOS) or data cut-off (DCO) which occurred earliest; median[min,max] duration 4.06[0.2,23.7] mons. For 'Docetaxel, then Switched to AMG 510', from FD to EOS/DCO which occurred earliest; median[min,max] duration 7.97[0.8,15.2] mons. Mortality:from randomization until death or DCO; median[min,max] time on study 14.78[0.2,24.3] mons.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Docetaxel78/174 (44.8%)67/151 (44.4%)129/151 (85.4%)
AMG 510109/171 (63.7%)91/169 (53.8%)151/169 (89.3%)
Docetaxel, Then Switched to AMG 51017/46 (37%)26/46 (56.5%)35/46 (76.1%)
Most frequent serious events
Showing 10 of 156
Most frequent serious events
EventDocetaxelAMG 510Docetaxel, Then Switched to AMG 510
Non-small cell lung cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)5/15118/1699/46
PneumoniaInfections and infestations10/1511/1692/46
Febrile neutropeniaBlood and lymphatic system disorders7/1510/1690/46
NauseaGastrointestinal disorders1/1512/1692/46
Back painMusculoskeletal and connective tissue disorders0/1510/1692/46
DyspnoeaRespiratory, thoracic and mediastinal disorders4/1512/1692/46
AnaemiaBlood and lymphatic system disorders5/1511/1690/46
DiarrhoeaGastrointestinal disorders2/1515/1690/46
Respiratory failureRespiratory, thoracic and mediastinal disorders4/1511/1690/46
Angina pectorisCardiac disorders0/1510/1691/46
Most frequent other events
Showing 10 of 42
Most frequent other events
EventDocetaxelAMG 510Docetaxel, Then Switched to AMG 510
DiarrhoeaGastrointestinal disorders37/15170/16914/46
FatigueGeneral disorders43/15127/1696/46
NauseaGastrointestinal disorders36/15143/1696/46
AlopeciaSkin and subcutaneous tissue disorders35/1513/1690/46
Decreased appetiteMetabolism and nutrition disorders29/15139/1695/46
AnaemiaBlood and lymphatic system disorders30/15128/1695/46
ConstipationGastrointestinal disorders29/15122/1693/46
DyspnoeaRespiratory, thoracic and mediastinal disorders25/15130/1695/46
CoughRespiratory, thoracic and mediastinal disorders25/15122/1694/46
ArthralgiaMusculoskeletal and connective tissue disorders21/15126/1694/46

Baseline characteristics

As pre-specified in the statistical analysis plan, data are presented for all randomized participants according to original treatment assignment, regardless of whether participants switched from receiving docetaxel to receiving AMG 510.

Age, Continuous
Age, Continuous(years)AMG 510DocetaxelTotal
Mean63.4 ± 9.963.6 ± 9.163.5 ± 9.5
Sex: Female, Male
Sex: Female, Male(Participants)AMG 510DocetaxelTotal
Female6279141
Male10995204
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)AMG 510DocetaxelTotal
Hispanic or Latino5914
Not Hispanic or Latino165163328
Unknown or Not Reported123
Race (NIH/OMB)
Race (NIH/OMB)(Participants)AMG 510DocetaxelTotal
American Indian or Alaska Native000
Asian212243
Native Hawaiian or Other Pacific Islander000
Black or African American202
White142144286
More than one race101
Unknown or Not Reported5813
08

Study locations

274 sites
  • Pacific Cancer Medical Center Inc
    Anaheim, California 92801, United States
  • City of Hope National Medical Center
    Duarte, California 91010, United States
  • Pacific Shores Medical Group Long Beach
    Long Beach, California 90813, United States
  • University of California Los Angeles
    Los Angeles, California 90095-1772, United States
  • University of California Los Angeles
    Los Angeles, California 90095, United States
  • University of California at Davis Medical Center
    Sacramento, California 95817, United States
  • Ridley Tree Cancer Center
    Santa Barbara, California 93105, United States
  • University of California San Francisco Mission Hall
    Stanford, California 94305, United States
  • Harbor University of California Los Angeles Medical Center
    Torrance, California 90502, United States
  • Rocky Mountain Cancer Centers
    Denver, Colorado 80218, United States
  • Danbury Hospital
    Norwalk, Connecticut 06856, United States
  • Medical Oncology Hematology Consultants Helen F Graham Cancer Center
    Newark, Delaware 19713, United States
  • Washington Cancer Institute at MedStar Washington Hospital
    Washington D.C., District of Columbia 20010, United States
  • Florida Cancer Specialists - Fort Myers
    Fort Myers, Florida 33901, United States
  • Memorial Regional Hospital
    Hollywood, Florida 33021, United States
  • Florida Cancer Specialists Research North
    St. Petersburg, Florida 33705, United States
  • Florida Cancer Specialists Research Panhandle
    Tallahassee, Florida 32308, United States
  • Emory University
    Atlanta, Georgia 30332, United States
  • Northside Hospital, Incorporated
    Atlanta, Georgia 30341, United States
  • Affiliated Oncologists, LLC
    North Chicago, Illinois 60064, United States
  • Fort Wayne Medical Oncology and Hematology
    Fort Wayne, Indiana 46804, United States
  • Willis Knighton Cancer Center
    Shreveport, Louisiana 71103, United States
  • Maryland Oncology Hematology PA
    Clinton, Maryland 20735, United States
  • New York Cancer and Blood Specialists
    Lowell, Massachusetts 01854, United States
  • University of Michigan
    Ann Arbor, Michigan 48109-1274, United States
  • Center for Oncology Clinical Trials
    Grand Rapids, Michigan 49503, United States
  • Minnesota Oncology Hematology PA
    Minneapolis, Minnesota 55404, United States
  • HCA Midwest Health Kansas City
    Kansas City, Missouri 64132, United States
  • Comprehensive Cancer Centers of Nevada
    Las Vegas, Nevada 89169, United States
  • Summit Medical Group
    Florham Park, New Jersey 07932, United States
  • New York Oncology Hematology, PC
    Albany, New York 12208, United States
  • United States Oncology Regulatory Affairs Corporate Office
    Albany, New York 12208, United States
  • Northwell Health Monter Cancer Center
    Lake Success, New York 11042, United States
  • Montefiore Einstein Center for Cancer Care
    The Bronx, New York 10461, United States
  • James J Peters VA Medical Center
    The Bronx, New York 10468, United States
  • Wake Forest Baptist Health
    Winston-Salem, North Carolina 27157, United States
  • Oncology Hematology Care Inc
    Cincinnati, Ohio 45219, United States
  • Northwest Cancer Specialists - Vancouver
    Portland, Oregon 97227, United States
  • Charleston Oncology
    Charleston, South Carolina 29414, United States
  • Saint Francis Hospital, Inc
    Greenville, South Carolina 29607, United States
  • Tennessee Oncology PLLC
    Chattanooga, Tennessee 37404, United States
  • Tennessee Cancer Specialists
    Knoxville, Tennessee 37909, United States
  • Tennessee Oncology
    Nashville, Tennessee 37203, United States
  • Texas Oncology-Bedford
    Bedford, Texas 76022, United States
  • Texas Oncology Baylor
    Dallas, Texas 75246, United States
  • UT Southwestern Medical Center
    Dallas, Texas 75390, United States
  • The Center for Cancer and Blood Disorders
    Fort Worth, Texas 76104, United States
  • Valley Cancer Associates
    Harlingen, Texas 78550, United States
  • University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • US Oncology Research Investigational Products Center
    Irving, Texas 75063, United States
  • Hope Cancer Center
    Tyler, Texas 75701, United States
  • Intermountain Medical Center
    Murray, Utah 84107, United States
  • Virginia Cancer Specialists, PC
    Fairfax, Virginia 22031, United States
  • Virginia Oncology Associates
    Norfolk, Virginia 23502, United States
  • Blacktown Hospital
    Blacktown, New South Wales 2148, Australia
  • Chris OBrien Lifehouse
    Camperdown, New South Wales 2050, Australia
  • St George Hospital
    Kogarah, New South Wales 2217, Australia
  • Liverpool Hospital
    Liverpool, New South Wales 2170, Australia
  • Prince Charles Hospital
    Chermside, Queensland 4032, Australia
  • Princess Alexandra Hospital
    Woolloongabba, Queensland 4102, Australia
  • The Queen Elizabeth Hospital
    Woodville South, South Australia 5011, Australia
  • Monash Medical Centre
    Clayton, Victoria 3168, Australia
  • Peter MacCallum Cancer Centre
    Melbourne, Victoria 3000, Australia
  • St John of God Healthcare
    Subiaco, Western Australia 6008, Australia
  • Institute Jules Bordet
    Brussels, 1000, Belgium
  • Universite Catholique de Louvain Cliniques Universitaires Saint Luc
    Brussels, 1200, Belgium
  • Grand Hopital de Charleroi
    Charleroi, 6000, Belgium
  • Universitair Ziekenhuis Antwerpen
    Edegem, 2650, Belgium
  • Universitair Ziekenhuis Gent
    Ghent, 9000, Belgium
  • Universitair Ziekenhuis Leuven - Campus Gasthuisberg
    Leuven, 3000, Belgium
  • Centre Hospitalier Universitaire de Liege
    Liège, 4000, Belgium
  • AZ Delta Campus Rumbeke
    Roeselare, 8800, Belgium
  • Algemeen Ziekenhuis Nikolaas Campus Sint Niklaas
    Sint-Niklaas, 9100, Belgium
  • Hospital de Caridade de Ijui
    Ijuí, Rio Grande do Sul 98700-000, Brazil
  • Hospital Sao Lucas da Pontificia Universidade Catolica do Rio Grande do Sul
    Porto Alegre, Rio Grande do Sul 90610-000, Brazil
  • Sociedade Beneficente de Senhoras Hospital Sirio Libanes
    São Paulo, São Paulo 01308-050, Brazil
  • Beneficencia Portuguesa de Sao Paulo
    São Paulo, São Paulo 01321-001, Brazil
  • Oncologia Rede D´Or
    São Paulo, São Paulo 04501-000, Brazil
  • Hospital Israelita Albert Einstein
    São Paulo, São Paulo 05652-900, Brazil
  • Hospital de Base de Sao Jose do Rio Preto
    São José Do Rio Preto, São Paulo 15090-000, Brazil
  • Fundacao Antonio Prudente - Hospital A C Camargo
    São Paulo, São Paulo 01509-900, Brazil
  • Centro de Tratamento de Tumores Botafogo
    Rio de Janeiro, 22250-905, Brazil
  • Instituto Coi
    Rio de Janeiro, 22793-080, Brazil
  • Tom Baker Cancer Centre
    Calgary, Alberta T2N 4N2, Canada
  • Cross Cancer Institute
    Edmonton, Alberta T6G 1Z2, Canada
  • Juravinski Cancer Centre
    Hamilton, Ontario L8V 5C2, Canada
  • London Health Sciences Centre
    London, Ontario N6A 5W9, Canada
  • The Ottawa Hospital Cancer Centre
    Ottawa, Ontario K1H 8L6, Canada
  • Princess Margaret Cancer Centre
    Toronto, Ontario M5G 2M9, Canada
  • Centre Hospitalier de L'Universite de Montreal Hopital Notre-Dame
    Montreal, Quebec H2X 3E4, Canada
  • Herlev og Gentofte Hospital
    Herlev, 2730, Denmark
  • Rigshospitalet
    København, 2100, Denmark
  • Odense Universitetshospital
    Odense C, 5000, Denmark
  • Docrates Syopasairaala
    Helsinki, 00180, Finland
  • Helsingin Yliopistollinen Keskussairaala
    Helsinki, 00290, Finland
  • Oulu University Hospital
    Oulu, 90220, Finland
  • Turku University Hospital
    Turku, 20520, Finland
  • Centre Hospitalier Regional Universitaire - Hopital Morvan
    Brest, 29609, France
  • Centre Hospitalier Intercommunal de Créteil
    Créteil, 94010, France
  • Centre Hospitalier Universitaire de Grenoble - Hopital Nord Michallon
    Grenoble, 38700, France

Showing the first 100 of 274 sites across 23 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Waterhouse DM, Rothschild S, Dooms C, Mennecier B, Bozorgmehr F, Majem M, van den Heuvel MH, Linardou H, Chul Cho B, Roberts-Thomson R, Tanaka K, Blais N, Schvartsman G, Holmskov Hansen K, Chmielewska I, Forster MD, Giannopoulou C, Stollenwerk B, Obiozor CC, Wang Y, Novello S. Patient-reported outcomes in CodeBreaK 200: Sotorasib versus docetaxel for previously treated advanced NSCLC with KRAS G12C mutation. Lung Cancer. 2024 Oct;196:107921. doi: 10.1016/j.lungcan.2024.107921. Epub 2024 Aug 6. PubMed 39303400 ↗
  • Skoulidis F, Li BT, Hochmair M, Govindan R, Vincent M, van der Wekken AJ, Reguart Aransay N, O'Byrne KJ, Girard N, Griesinger F, Nishio M, Hafliger S, Lindsay C, Reinmuth N, Paulus A, Papakotoulas P, Kim SW, Ferreira CG, Pasello G, Duruisseaux M, Gennatas S, Dimou A, Mehta B, Kormany W, Nduka C, Sylvester BE, Ardito-Abraham C, Wang Y, de Langen AJ. Pooled safety analysis and management of sotorasib-related adverse events in KRAS G12C-mutated advanced non-small cell lung cancer. Oncologist. 2025 Jan 17;30(1):oyae356. doi: 10.1093/oncolo/oyae356. PubMed 39846981 ↗
  • Skoulidis F, Li BT, de Langen AJ, Hong DS, Lena H, Wolf J, Dy GK, Curioni Fontecedro A, Tomasini P, Velcheti V, van der Wekken AJ, Dooms C, Paz-Ares Rodriguez L, Mountzios G, Sacher A, Nadal E, Couraud S, Kim SW, O'Byrne K, Rocco D, Toyozawa R, Chmielewska I, Lindsay CR, Hindoyan A, Mukundan L, Wilmanski T, Anderson A, Ardito-Abraham C, Pati A, Reddy A, Mehta B, Schuler M. Molecular determinants of sotorasib clinical efficacy in KRASG12C-mutated non-small-cell lung cancer. Nat Med. 2025 Aug;31(8):2755-2767. doi: 10.1038/s41591-025-03732-5. Epub 2025 May 28. PubMed 40437272 ↗
  • de Langen AJ, Johnson ML, Mazieres J, Dingemans AC, Mountzios G, Pless M, Wolf J, Schuler M, Lena H, Skoulidis F, Yoneshima Y, Kim SW, Linardou H, Novello S, van der Wekken AJ, Chen Y, Peters S, Felip E, Solomon BJ, Ramalingam SS, Dooms C, Lindsay CR, Ferreira CG, Blais N, Obiozor CC, Wang Y, Mehta B, Varrieur T, Ngarmchamnanrith G, Stollenwerk B, Waterhouse D, Paz-Ares L; CodeBreaK 200 Investigators. Sotorasib versus docetaxel for previously treated KRAS G12C-mutated non-small-cell lung cancer: a plain language summary. Future Oncol. 2025 Apr;21(9):1033-1044. doi: 10.1080/14796694.2025.2474789. Epub 2025 Mar 24. PubMed 40129223 ↗
  • Dingemans AC, Syrigos K, Livi L, Paulus A, Kim SW, Chen Y, Felip E, Griesinger F, Ohashi K, Zalcman G, Hughes BGM, Sorensen JB, Blais N, Ferreira CGM, Lindsay CR, Dziadziuszko R, Ward PJ, Obiozor CC, Wang Y, Peters S. Intracranial activity of sotorasib vs docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer from a global, phase 3, randomized controlled trial. Lung Cancer. 2025 Sep;207:108683. doi: 10.1016/j.lungcan.2025.108683. Epub 2025 Jul 29. PubMed 40774040 ↗
  • de Langen AJ, Johnson ML, Mazieres J, Dingemans AC, Mountzios G, Pless M, Wolf J, Schuler M, Lena H, Skoulidis F, Yoneshima Y, Kim SW, Linardou H, Novello S, van der Wekken AJ, Chen Y, Peters S, Felip E, Solomon BJ, Ramalingam SS, Dooms C, Lindsay CR, Ferreira CG, Blais N, Obiozor CC, Wang Y, Mehta B, Varrieur T, Ngarmchamnanrith G, Stollenwerk B, Waterhouse D, Paz-Ares L; CodeBreaK 200 Investigators. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial. Lancet. 2023 Mar 4;401(10378):733-746. doi: 10.1016/S0140-6736(23)00221-0. Epub 2023 Feb 7. PubMed 36764316 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2020 to primary completion in Aug 2022, 25 months.

Results were first posted in May 2023, 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2020
First posted
Mar 11, 2020
StartActual
Jun 4, 2020
Primary completionActual
Aug 2, 2022
CompletionActual
Jun 24, 2026
Results first posted
May 10, 2023
Last update
Jul 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04303780
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Mar 11, 2020
Start date
Jun 4, 2020
Primary completion
Aug 2, 2022
Completion
Jun 24, 2026
Results posted
May 10, 2023
Last update
Jul 22, 2026

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sotorasib

Start the discussion